Current strategies in the management of Barrett's esophagus

被引：4
作者：
Wang K.K. [1 ]
机构：
[1] Division of Gastroenterology and Hepatology, Saint Mary's Hospital, Mayo Clinic and College of Medicine, Rochester, MN 55905, 200 Second Street, SW
来源：
Current Gastroenterology Reports | 2005年 / 7卷 / 3期
基金：
美国国家卫生研究院;
关键词：
Photodynamic Therapy; Endoscopic Mucosal Resection; Antireflux Surgery; Endoscopic Therapy; Argon Plasma Coagulation;
D O I：
10.1007/s11894-005-0034-9
中图分类号：
学科分类号：
摘要：
Barrett's esophagus has become a very important topic in gastroenterology. Its management may vary from essentially a surveillance strategy to highly invasive esophagectomy. The variation in management strategies has occurred because of the current perceptions regarding cancer risks, which range from almost negligible to an incidence of 30% in high-grade dysplasia. Although it is clear that most patients with Barrett's esophagus without dysplasia will not require therapy, the prospect of continued surveillance is unpleasant at best. Promising future tools and techniques for surveillance and treatment are described in this review. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：196 / 201
页数：5
相关论文
共 38 条
  • [1] Shaheen N.J., Crosby M.A., Bozymski E.M., Sandler R.S., Is there publication bias in the reporting of cancer risk in Barrett's esophagus?, Gastroenterology, 119, pp. 333-338, (2000)
  • [2] Montgomery E., Bronner M.P., Goldblum J.R., Et al., Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation, Human Pathol., 32, pp. 368-378, (2001)
  • [3] Krishnadath K.K., Reid B.J., Wang K.K., Biomarkers in Barrett esophagus, Mayo Clin. Proc., 76, pp. 438-446, (2001)
  • [4] Rabinovitch P.S., Longton G., Blount P.L., Et al., Predictors of progression in Barrett's esophagus III: Baseline flow cytometric variables, Am. J. Gastroenterol., 96, pp. 3071-3083, (2001)
  • [5] Reid B.J., Prevo L.J., Galipeau P.C., Et al., Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression, Am. J. Gastroenterol., 96, pp. 2839-2848, (2001)
  • [6] Sampliner R.E., Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus, Am. J. Gastroenterol., 89, pp. 1844-1848, (1994)
  • [7] Buttar N.S., Wang K.K., Sebo T.J., Et al., Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma, Gastroenterology, 120, pp. 1630-1639, (2001)
  • [8] Ye W., Chow W.H., Lagergren J., Et al., Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastro-esophageal reflux diseases and after antireflux surgery, Gastroenterology, 121, pp. 1286-1293, (2001)
  • [9] Buttar N.S., Wang K.K., Anderson M.A., Et al., The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: An in vitro study, J. Natl. Cancer Inst., 94, pp. 422-429, (2002)
  • [10] Buttar N.S., Wang K.K., Leontovich O., Et al., Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus, Gastroenterology, 122, pp. 1101-1112, (2002)
1234